What is the recommended starting dose of glipizide (a sulfonylurea oral hypoglycemic agent) for a patient with type 2 diabetes mellitus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 12, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Glipizide Once Daily Dosing

Starting Dose

The recommended starting dose of glipizide is 5 mg once daily, given approximately 30 minutes before breakfast. 1

  • For geriatric patients, debilitated or malnourished patients, and those with impaired renal or hepatic function, the initial dose should be 2.5 mg once daily to avoid hypoglycemic reactions 1

  • Patients with renal impairment (CrCl 30-50 mL/min/1.73 m²) should initiate glipizide conservatively at 2.5 mg once daily and titrate slowly to avoid hypoglycemia 2

Dose Titration

Dosage adjustments should ordinarily be in increments of 2.5–5 mg, as determined by blood glucose response, with at least several days elapsing between titration steps. 1

  • If response to a single dose is not satisfactory, dividing that dose may prove effective 1

Maximum Dosing

The maximum recommended once daily dose is 15 mg. 1

  • Doses above 15 mg should ordinarily be divided and given before meals of adequate caloric content 1

  • The maximum recommended total daily dose is 40 mg 1

  • Total daily doses above 15 mg should ordinarily be divided 1

  • Total daily doses above 30 mg have been safely given on a twice-daily basis to long-term patients 1

Maintenance Dosing

Some patients may be effectively controlled on a once-a-day regimen, while others show better response with divided dosing 1

Clinical Context and Positioning

Sulfonylureas like glipizide are positioned as second-line agents after metformin, typically used in combination therapy when metformin monotherapy fails to achieve glycemic targets 2

  • GLP-1 receptor agonists and SGLT2 inhibitors are generally preferred over sulfonylureas for patients with diabetic kidney disease due to superior cardiovascular and renal outcomes 2

Common Pitfalls to Avoid

  • Do not start with higher doses in elderly or renally impaired patients – this substantially increases hypoglycemia risk 1

  • Do not advance doses more frequently than every several days – allow adequate time to assess glycemic response 1

  • Do not exceed 15 mg as a single daily dose – doses above this threshold should be divided 1

  • When combining glipizide with insulin therapy, reduce insulin doses by approximately 20% to minimize hypoglycemia risk, as the combination significantly increases this risk 3

References

Guideline

Glipizide Dosing for Type 2 Diabetes Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Managing Glipizide and Insulin Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.